Online Events

Archives

Excipients Innovations 2015

Excipients Innovations 2015

Online Event

This event will examine the drug excipients market, from the historical events that have defined the sector to the debates going on at the moment to predictions about the demands that will drive it in the future.How did the DEG tragedies of the last century...

View

Bioavailability Challenge 2014

Bioavailability Challenge 2014

Online Event

It is a well-established principal that even the most promising API, monoclonal antibody or therapeutic peptide can only be turned into an effective and marketable drug if formulated in such a way that it reaches the blood stream and is bioavailable.But,...

View

From the lab to the factory

From the lab to the factory

Online Event

How do you take a successful bioavailability solution from the laboratory to the pilot plant and on to commercial-scale production? What are the potential pitfalls and considerations involved in successfully scaling-up the production of a poorly soluble...

View

Shaping amorphous solid dispersion

Shaping amorphous solid dispersion

Online Event

Creating an Amorphous Solid Dispersion (ASD) is an increasingly popular way of improving Active Pharmaceutical Ingredient (API) solubility. But while the approach can be successful, the big problem is demonstrating ASD stability, preventing ingredients...

View

Oncology Trials Outsourcing 2011

Oncology Trials Outsourcing 2011

Online Event

Cancer drug development is the most complex challenge faced by the drug industry today, with clinical trials being the most technically difficult, time consuming and expensive aspect of the process. 
Recruiting patients, monitoring sites and...

View

Oncology Trials Outsourcing - Cutting Edge

Oncology Trials Outsourcing - State of the market

Online Event

“Oncology has become one of the major focus areas for pharmaceutical and biotechnology companies because of a high number of unmet needs for improved treatments in different types of cancer. In 2009, around 40,000 Phase I, II and III trials were listed...

View